Medicine & Life Sciences

1. Primary Myelofibrosis 100%
2. Myelodysplastic Syndromes 70%
3. Survival 62%
4. Acute Myeloid Leukemia 62%
5. Mutation 39%
6. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 39%
7. Karyotype 39%
8. venetoclax 38%
9. Essential Thrombocythemia 23%
10. pomalidomide 19%
11. Therapeutics 19%
12. 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 19%
13. Anemia 19%
14. Blast Crisis 19%
15. Systemic Mastocytosis 17%
16. Polycythemia Vera 16%
17. Cytogenetics 15%
18. Leukemia 14%
19. Neoplasms 14%
20. Hematologic Neoplasms 13%
21. Myeloid Sarcoma 11%
22. High-Throughput Nucleotide Sequencing 11%
23. Thrombocytosis 11%
24. Induction Chemotherapy 11%
25. Azacitidine 11%
26. Decitabine 10%
27. Bone Marrow 10%
28. Leukemia, Myeloid, Chronic Phase 9%
29. Protein-Tyrosine Kinases 9%
30. Platelet Count 9%
31. N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide 9%
32. Second Primary Neoplasms 9%
33. Mast-Cell Leukemia 8%
34. Transplants 8%
35. midostaurin 8%
36. Peripheral Nervous System Diseases 8%
37. Elderly 8%
38. Vacuoles 8%
39. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8%
40. sapacitabine 8%
41. imetelstat 8%
42. Fedratinib 7%
43. Thrombocytopenia 7%
44. Allogeneic Cells 7%
45. Splenomegaly 7%
46. Monosomy Chromosome 7 7%
47. anagrelide 6%
48. Cladribine 6%
49. Acute Promyelocytic Leukemia 6%
50. Chromosome 5q Deletion Syndrome 6%